• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

光动力疗法治疗典型的年龄相关性黄斑变性和息肉样脉络膜血管病变:日本兵库县的一项 30 个月的多中心研究。

Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan.

机构信息

Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.

Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

出版信息

Jpn J Ophthalmol. 2009 Nov;53(6):593-597. doi: 10.1007/s10384-009-0741-0. Epub 2009 Dec 18.

DOI:10.1007/s10384-009-0741-0
PMID:20020237
Abstract

PURPOSE

To evaluate the long-term effects of photodynamic therapy (PDT) on different phenotypes of age-related macular degeneration (AMD): typical AMD (tAMD) and polypoidal choroidal vasculopathy (PCV).

METHODS

A multicenter prospective study of 207 eyes of 201 patients (tAMD, 123 eyes; PCV, 84 eyes) treated with PDT. Sex, age, best-corrected visual acuity (BCVA), greatest linear dimension, and lesion type were evaluated for pretreatment factors. PDT frequency, BCVA at 30 months post-PDT, frequency of recurrence, and mean recurrence period were compared as posttreatment outcomes.

RESULTS

The 30 months post-PDT mean BCVA was significantly lower than the pre-PDT value in the tAMD group, but it remained unchanged in the PCV group. There was no difference in PDT frequency between the two groups. Multivariate analysis revealed that lesion type was the only predicting factor significantly associated with BCVA at 30 months post-PDT. The incidence of recurrence before 30 months post-PDT was not significantly different between the tAMD and PCV groups, whereas the mean duration of the PDT effect was significantly longer in the PCV group than in the tAMD group.

CONCLUSIONS

PDT may have some advantages for PCV patients, but not for tAMD patients. However, as PCV often recurred 12 months post-PDT, long-term observation after the treatment is crucial.

摘要

目的

评估光动力疗法(PDT)对不同表型年龄相关性黄斑变性(AMD)的长期效果:典型 AMD(tAMD)和息肉样脉络膜血管病变(PCV)。

方法

对 201 例 207 只眼(tAMD123 只眼,PCV84 只眼)进行 PDT 的多中心前瞻性研究。对治疗前的性别、年龄、最佳矫正视力(BCVA)、最大线性尺寸和病变类型等因素进行评估。比较 PDT 频率、治疗后 30 个月的 BCVA、复发频率和平均复发时间等治疗后结果。

结果

治疗后 30 个月的 tAMD 组平均 BCVA 明显低于治疗前,而 PCV 组则保持不变。两组 PDT 频率无差异。多变量分析显示,病变类型是与治疗后 30 个月 BCVA 唯一显著相关的预测因素。tAMD 和 PCV 两组在治疗后 30 个月前的复发率无显著差异,但 PCV 组 PDT 效果的平均持续时间明显长于 tAMD 组。

结论

PDT 对 PCV 患者可能有一些优势,但对 tAMD 患者没有。然而,由于 PCV 常在 PDT 后 12 个月复发,因此治疗后的长期观察至关重要。

相似文献

1
Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan.光动力疗法治疗典型的年龄相关性黄斑变性和息肉样脉络膜血管病变:日本兵库县的一项 30 个月的多中心研究。
Jpn J Ophthalmol. 2009 Nov;53(6):593-597. doi: 10.1007/s10384-009-0741-0. Epub 2009 Dec 18.
2
Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan.典型年龄相关性黄斑变性和息肉样脉络膜血管病变的光动力疗法比较评估:日本兵库县的一项多中心研究
Ophthalmologica. 2009;223(5):333-8. doi: 10.1159/000221837. Epub 2009 May 29.
3
Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up.5 年随访观察光动力疗法治疗典型新生血管性年龄相关性黄斑变性和息肉状脉络膜血管病变的疗效。
Jpn J Ophthalmol. 2013 May;57(3):301-7. doi: 10.1007/s10384-013-0237-9. Epub 2013 Mar 19.
4
One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.日本患者年龄相关性黄斑变性和息肉样脉络膜血管病变的光动力疗法一年期疗效
Ophthalmology. 2008 Jan;115(1):141-6. doi: 10.1016/j.ophtha.2007.02.031. Epub 2007 Jun 20.
5
The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.年龄相关性黄斑病变易感性2基因多态性与典型新生血管性年龄相关性黄斑变性及息肉状脉络膜血管病变表型的关联
Mol Vis. 2011 Apr 20;17:977-82.
6
Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.影响光动力疗法治疗后一年息肉样脉络膜血管病变患者视力预后的因素。
Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1233-9. doi: 10.1007/s00417-010-1365-2. Epub 2010 Mar 30.
7
[Polypoidal choroidal vasculopathy].[息肉样脉络膜血管病变]
Nippon Ganka Gakkai Zasshi. 2012 Mar;116(3):200-31; discussion 232. doi: 10.4264/numa.71.282.
8
Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.亚洲人年龄相关性黄斑变性和息肉样脉络膜血管病变的真实世界治疗结果。
Ophthalmol Retina. 2020 Apr;4(4):403-414. doi: 10.1016/j.oret.2019.10.019. Epub 2019 Nov 9.
9
Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy.减少光动力疗法联合玻璃体内雷珠单抗治疗典型年龄相关性黄斑变性和息肉状脉络膜血管病变的两年疗效。
Jpn J Ophthalmol. 2013 May;57(3):283-93. doi: 10.1007/s10384-013-0234-z. Epub 2013 Feb 15.
10
Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.抗血管内皮生长因子药物联合光动力疗法治疗息肉状脉络膜血管病变的长期疗效和安全性。
Indian J Ophthalmol. 2018 Aug;66(8):1119-1127. doi: 10.4103/ijo.IJO_1222_17.

引用本文的文献

1
Direct analysis of the actin-filament formation effect in photodynamic therapy.光动力疗法中肌动蛋白丝形成效应的直接分析。
RSC Adv. 2022 Feb 16;12(10):5878-5889. doi: 10.1039/d1ra09291j.
2
Polypoidal choroidal vasculopathy: An update on current management and review of literature.息肉样脉络膜血管病变:当前治疗进展及文献综述
Taiwan J Ophthalmol. 2019 Apr-Jun;9(2):72-92. doi: 10.4103/tjo.tjo_35_18.
3
The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.

本文引用的文献

1
Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan.典型年龄相关性黄斑变性和息肉样脉络膜血管病变的光动力疗法比较评估:日本兵库县的一项多中心研究
Ophthalmologica. 2009;223(5):333-8. doi: 10.1159/000221837. Epub 2009 May 29.
2
Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments.预测到2050年与年龄相关的黄斑变性:新疗法的潜在影响。
Arch Ophthalmol. 2009 Apr;127(4):533-40. doi: 10.1001/archophthalmol.2009.58.
3
Coding variant I62V in the complement factor H gene is strongly associated with polypoidal choroidal vasculopathy.
血管内皮生长因子抑制剂的应用及息肉样脉络膜血管病变的补充治疗选择:一种新生血管性年龄相关性黄斑变性的亚型。
Int J Mol Sci. 2018 Sep 3;19(9):2611. doi: 10.3390/ijms19092611.
4
Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.在1+PRN方案下光动力疗法、玻璃体内注射雷珠单抗及联合治疗息肉状脉络膜血管病变的疗效比较
BMC Ophthalmol. 2018 Jun 20;18(1):144. doi: 10.1186/s12886-018-0801-7.
5
Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia.马来西亚一家三级医疗机构中雷珠单抗和光动力疗法的患病率及治疗模式。
Int J Ophthalmol. 2017 Dec 18;10(12):1889-1897. doi: 10.18240/ijo.2017.12.16. eCollection 2017.
6
HTRA1 promoter variant differentiates polypoidal choroidal vasculopathy from exudative age-related macular degeneration.HTRA1 启动子变异可区分息肉样脉络膜血管病变与渗出性年龄相关性黄斑变性。
Sci Rep. 2016 Jun 24;6:28639. doi: 10.1038/srep28639.
7
Polypoidal Choroidal Vasculopathy in Asians.亚洲人的息肉样脉络膜血管病变
J Clin Med. 2015 Apr 24;4(5):782-821. doi: 10.3390/jcm4050782.
8
Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration.维替泊芬光动力疗法治疗日本新生血管性年龄相关性黄斑变性患者的五年结果
Clin Ophthalmol. 2013;7:615-20. doi: 10.2147/OPTH.S43566. Epub 2013 Mar 27.
9
Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.玻璃体内雷珠单抗治疗渗出型年龄相关性黄斑变性(AMD)的疗效:1 年随访中典型新生血管性 AMD 与息肉状脉络膜血管病变的比较。
BMC Ophthalmol. 2013 Apr 4;13:10. doi: 10.1186/1471-2415-13-10.
10
Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up.5 年随访观察光动力疗法治疗典型新生血管性年龄相关性黄斑变性和息肉状脉络膜血管病变的疗效。
Jpn J Ophthalmol. 2013 May;57(3):301-7. doi: 10.1007/s10384-013-0237-9. Epub 2013 Mar 19.
补体因子H基因中的编码变体I62V与息肉状脉络膜血管病变密切相关。
Ophthalmology. 2009 Feb;116(2):304-10. doi: 10.1016/j.ophtha.2008.11.011.
4
Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy.息肉状脉络膜血管病变光动力疗法的两年结果
Am J Ophthalmol. 2008 Oct;146(4):513-519. doi: 10.1016/j.ajo.2008.05.025. Epub 2008 Jul 9.
5
Age-related macular degeneration: diagnosis and management.年龄相关性黄斑变性:诊断与管理
Br Med Bull. 2008;85:127-49. doi: 10.1093/bmb/ldn012.
6
Elastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.新生血管性年龄相关性黄斑变性和息肉状脉络膜血管病变中的弹性蛋白基因多态性
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1101-5. doi: 10.1167/iovs.07-1145.
7
Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.单次光动力疗法联合玻璃体内注射贝伐单抗治疗新生血管性年龄相关性黄斑变性。
Eur J Ophthalmol. 2008 Mar-Apr;18(2):297-300. doi: 10.1177/112067210801800222.
8
Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.抗血管内皮生长因子药物治疗新生血管性年龄相关性黄斑变性:将临床试验结果应用于日常患者的治疗
Am J Ophthalmol. 2007 Oct;144(4):627-37. doi: 10.1016/j.ajo.2007.06.039.
9
Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results.玻璃体内注射贝伐单抗治疗新生血管性年龄相关性黄斑变性:6个月和9个月的结果
Eye (Lond). 2008 Jan;22(1):82-6. doi: 10.1038/sj.eye.6702936. Epub 2007 Sep 21.
10
Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.玻璃体腔内注射贝伐单抗联合光动力疗法治疗新生血管性年龄相关性黄斑变性
Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):17-25. doi: 10.1007/s00417-007-0654-x. Epub 2007 Aug 15.